ABSTRACT
and systolic blood pressure with dapagliflozin were similar among patient subgroups defined by either eGFR estimate and were statistically significant and clinically meaningful with dapagliflozin 10 mg/day in most subgroups.
Conclusion:
The correlation between eGFRcr and eGFRcys was poor. Renal function assessed by eGFRcr may be underestimated, and some patients may be misdiagnosed with chronic kidney disease and/or unjustifiably deemed ineligible for certain antidiabetes medications. This is in consonance with guidelines suggesting using eGFRcys as a confirmatory measure when eGFRcr is between 45 and \60 mL/min/1.73 m 2 with no evidence of kidney damage and/or in other situations where eGFRcr may be unreliable.
INTRODUCTION
Patients with diabetes have an increased risk of chronic kidney disease (CKD) [1] , defined as an estimated glomerular filtration rate (eGFR) of \60 mL/min/1.73 m 2 or an albumin/creatinine ratio [30 mg/g for more than 3 months [2] . The prevalence of CKD among patients with diabetes in the National Health and Nutrition
Examination Survey (NHANES) from 2007 to 2012 was *40%, and *20% of the diabetes population had an eGFR\60 mL/min/1.73 m 2 [3] . Diabetes is also the major cause of end-stage renal disease (ESRD) [3] . Because GFR is the best overall measure of kidney function [2] , its accurate assessment is important for the diagnosis of CKD and for drug dosing considerations; many drugs, including some antidiabetes medications, are eliminated by the kidney and require dose adjustment in CKD or depend on kidney function for efficacy [4] .
Glomerular filtration rate can be directly measured by determining the clearance of exogenous filtration markers such as iothalamate, iohexol, or inulin [5] . However, these methods are time consuming, expensive, and impractical for routine clinical use.
Therefore, estimates of GFR based on serum concentrations of the endogenous filtration marker creatinine are commonly used to assess kidney function. Serum creatinine concentrations may be affected by several factors, including age, sex, ethnicity, muscle mass, dietary protein intake, and overall health [6, 7] . Various creatinine-based equations to assess GFR, most notably the Modification of Diet in Renal Disease (MDRD) and CKD Epidemiology Collaboration (CKD-EPI) [2] , have been developed to account for such factors. These equations may not be suitable in all patients and may underestimate GFR in individuals with eGFR 60-80 mL/min/1.73 m 2 [8] , and notably in patients with eGFR 45 to \60 mL/min/1.73 m 2 [9] .
Because of the limitations of creatinine-based eGFR (eGFRcr), estimates of GFR based on cystatin C (eGFRcys) have been proposed as an alternative, less variable measure of eGFR [10] . Cystatin C is a cysteine protease inhibitor that is constitutively produced by all nucleated cells, filtered by the glomerulus, and reabsorbed by tubular cells, but not secreted by the renal tubules [11] . Cystatin C is less influenced than creatinine by the individual factors noted above, although small effects of diabetes, inflammation, body mass index, thyroid status, and steroid therapy on serum cystatin C concentrations have been described [2, 12] . Estimates of GFR based on cystatin C appear to correlate better than ones based on creatinine with morbidity and mortality in diverse patient populations, including those with CKD [9] . In addition, serum cystatin C concentration may be a better predictor of progression to ESRD than serum creatinine in individuals with type 2 diabetes and albuminuria [13] . Based on these considerations, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest using eGFRcys as a confirmatory measure when eGFRcr is between 45 and \60 mL/min/1.73 m 2 in patients with no evidence of kidney damage and/or in other situations in which eGFRcr may be unreliable [2] . 
METHODS
This was a post hoc analysis that included data pooled from 9 dapagliflozin phase 3, randomized, double-blind, placebo-controlled, 24-week studies in adult patients (C18 years of age) with type 2 diabetes mellitus. Dapagliflozin 5 or 10 mg/day or placebo was administered as monotherapy in treatment-naive patients (ClinicalTrials.gov identifier, NCT00528372) [19] ; as initial combination therapy with metformin (NCT00859898) [20] ; and as add-on to the following: metformin (NCT00528879 and NCT00855166) [21, 22] , glimepiride (NCT00680745) [23] , sitagliptin ± metformin (NCT00984867) [24] , insulin ± up to 2 other antidiabetes medications (NCT00673231) [25] , usual care in patients with cardiovascular disease (NCT01042977) [26] , and usual care in patients with cardiovascular disease and hypertension (NCT01031680) [27] . Study designs, inclusion and exclusion criteria, and primary findings for these 9 studies have been previously reported in detail [19] [20] [21] [22] [23] [24] [25] [26] [27] and baseline value and study by baseline value were included as covariates for each GFR estimation method. P values (without multiplicity adjustment) for treatment comparisons were estimated from respective t tests. All statistical analyses were performed using SAS procedures (SAS version 9.2, SAS Institute, Cary, NC, USA). Safety and tolerability based on adverse events (AEs), serious AEs (SAEs), hypoglycemia, laboratory abnormalities, and vital signs were assessed in all patients who received study medication.
Hypoglycemia events excluded data after rescue treatment. Major hypoglycemia was defined as a symptomatic episode requiring third-party assistance owing to severe impairment of consciousness or behavior, with plasma glucose \3.0 mmol/L and prompt recovery with glucose or glucagon administration. Minor hypoglycemia was a symptomatic or asymptomatic episode with plasma glucose \3.5 mmol/L. Other hypoglycemia was a suggestive episode that was reported but did not meet the criteria for major or minor episodes.
RESULTS
A total of 4745 patients were included in this analysis ( Within the eGFR ranges estimated by either creatinine or cystatin C, the proportion of patients with C1 AE was similar between placebo and dapagliflozin-treated patients (Table 3) when measured by cystatin C [9] . Also, eGFRcys, alone or in combination with eGFRcr, showed a better correlation between eGFR category and risk of death and ESRD than In our analysis, changes from baseline in HbA 1c with dapagliflozin compared with placebo appeared greater in patients with eGFR C60 mL/min/1.73 m 2 than in those with eGFR 30 to \60 mL/min/1.73 m 2 , regardless of calculation method. This is consistent with the mechanism of action of SGLT2 inhibitors [14] and with published studies of dapagliflozin [15] and other SGLT2 inhibitors, in which the efficacy decreased with lower GFR [16, 17] .
Changes in body weight and SBP were generally similar across the 2 eGFR ranges. The . Whether these findings can be generalized to other races and age groups is unknown, but because serum cystatin C concentrations appear to be less affected by age and race than serum creatinine [12] , eGFRcys may be a more accurate estimate of GFR in some patients.
CONCLUSION
The results of this analysis suggest that the correlation between eGFRcys and eGFRcr in 
